Arcturus Therapeutics
ARCT
18 hedge funds and large institutions have $6.98M invested in Arcturus Therapeutics in 2018 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 5 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
89% more capital invested
Capital invested by funds: $3.69M → $6.98M (+$3.29M)
1.37% more ownership
Funds ownership: 6.28% → 7.65% (+1.4%)
0% more funds holding
Funds holding: 18 → 18 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
91% less call options, than puts
Call options by funds: $2K | Put options by funds: $22K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$1.31M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$171K |
| 3 |
BlackRock
New York
|
+$129K |
| 4 |
Morgan Stanley
New York
|
+$90.4K |
| 5 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
+$82.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$312K |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$183K |
| 3 |
KCM
Kingdon Capital Management
New York
|
-$156K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$54K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$51.8K |
ARCT Hedge Fund Activity: Q2 2018 in Review
18 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q2 2018, worth a combined $6.98M — up 89% from $3.69M a quarter earlier.
Fund positioning in ARCT was balanced in Q2 2018: 5 funds opened new positions, 5 closed out, 5 added to existing stakes and 2 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $1.31M. The largest seller was Franklin Resources, exiting entirely with an estimated $312K sold.
- 18 institutional investors held Arcturus Therapeutics (ARCT) as of Q2 2018, unchanged from Q1 2018.
- Funds reported $6.98M of Arcturus Therapeutics stock for Q2 2018, up 89% quarter-over-quarter.
- 5 funds opened new Arcturus Therapeutics positions in Q2 2018 and 5 closed out, a net change of 0 holders.
- The largest Arcturus Therapeutics buyer in Q2 2018 was ARK Investment Management, an estimated $1.31M added.
- The largest Arcturus Therapeutics seller in Q2 2018 was Franklin Resources, an estimated $312K sold.
Based on aggregated 13F filings for Q2 2018.